Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Endometriosis-associated intestinal tumor: A Case Report and Review of Literature with Comprehensive Proteomic Analysis

ABSTRACT: This study reports a rare case of endometriosis-associated intestinal tumor (EAIT) in a 53-year-old woman who presented with rectal bleeding. Imaging and histopathology confirmed endometrioid adenocarcinoma arising from rectal endometriosis with ovarian metastasis. The patient underwent posterior total pelvic exenteration followed by adjuvant chemotherapy and has remained disease-free for 3.5 years. Comprehensive proteomic profiling of the tumor identified 9,294 proteins, with data deposited in the jPOST repository. This case highlights the diagnostic challenges, clinical management strategies, and biological insights of EAIT, providing a valuable reference for future comparative and translational research.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Yuki Yoshimatsu

PROVIDER: PXD067723 | JPOST Repository | Tue Jun 30 00:00:00 BST 2026

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	C23005_Re.pg_matrix.tsv	Tabular
	C23005_Re.pr_matrix.tsv	Tabular
	C23005_Re.tsv	Tabular
	N_Cjo228_032.mzML	Mzml
	N_Cjo228_032.raw	Raw

Items per page:

1 - 5 of 7

Publications

Endometriosis-Associated Intestinal Tumor: A Case Report and Literature Review with Comprehensive Proteomic Data.

Toyota Naoyuki N Yoshimatsu Yuki Y Kamozawa Chihiro C Nakanishi Ryo R Fujita Shin S Abe Makoto M Konno Ryo R Kawashima Yusuke Y Kondo Tadashi T

Surgical case reports 20260311 1

<h4>Introduction</h4>Endometriosis-associated intestinal tumors (EAITs) are rare malignancies that arise from ectopic endometrial tissue, and their clinical and molecular characteristics remain poorly defined.<h4>Case presentation</h4>We report a 53-year-old woman who presented with rectal bleeding. Imaging revealed a rectal mass invading the uterus. An initial endoscopic biopsy was inconclusive; however, a subsequent CT-guided biopsy confirmed adenocarcinoma. Immunohistochemical analysis sugges ...[more]

PMID: 41853299

Similar Datasets

The impact of neoadjuvant chemotherapy on tumor microenvironment in advanced high-grade serous carcinoma

Project description:High-grade serous ovarian, fallopian tube or peritoneal carcinoma is an aggressive subtype that frequently develops resistance to chemotherapy. It remains controversial whether the resistance is caused by the acquisition of new molecular aberrations or alternatively through the selection of rare preexisting tumor clones. To address this question, we applied single cell RNA sequencing to depict the tumor landscape of a single case of advanced high-grade serous fallopian tube carcinoma during neoadjuvant chemotherapy (NACT).

2022-08-16 | GSE191301 | GEO

Extraskeletal Osteosarcoma Harboring ETV6:NTRK3 Fusion Treated Successfully with Larotrectinib: A Case study [Archer Fusion Plex Pan Solid Tumor v2 panel]

Project description:Background: Extraskeletal osteosarcoma (ESOS) is a rare, aggressive mesenchymal tumor with limited therapeutic options and a poor prognosis due to frequent metastases. Identifying targetable genetic alterations could improve treatment outcomes. The objective is to report the first worldwide case of ESOS harboring an ETV6::NTRK3 fusion and describe the clinical response to larotrectinib, a selective TRK inhibitor. Methods: Case report of a 74-year-old man with a rapidly enlarging, inoperable neck tumor measuring 7.9 x 7.1 x 6.6 cm. The case underwent histopathological, immunohistochemical, and molecular analyses, including targeted RNA sequencing using the Archer Fusion Plex Pan Solid Tumor v2 panel and DNA-based targeted analysis with the Ion Torrent Oncomine Comprehensive Assay Plus. The clinical course was monitored over an 8-month treatment period. Results: Molecular analysis revealed an actionable, in ESOS previously not described, ETV6::NTRK3 fusion. Treatment with larotrectinib (100 mg twice daily) led to a rapid clinical response within 3 weeks. MRI demonstrated partial remission after 2 months (4.7 x 3.9 x 2.8 cm), with further tumor shrinkage at 8 months (4.4 x 3.7 x 2.4 cm). Despite complications, including urothelial carcinoma recurrence requiring chemotherapy and surgery, larotrectinib was resumed with dose adjustments. No significant adverse effects related to TRK inhibition were observed. Conclusions: This case represents the first reported instance of ESOS with an NTRK fusion. The rapid and sustained response to larotrectinib highlights the potential of precision medicine in managing rare and aggressive tumors, emphasizing the importance of molecular profiling to identify actionable targets.

2025-12-04 | GSE308604 | GEO

Extraskeletal Osteosarcoma Harboring ETV6:NTRK3 Fusion Treated Successfully with Larotrectinib: A Case study [Ion Torrent Oncomine Comprehensive Assay Plus]

2025-12-04 | GSE308605 | GEO

A platform for efficient establishment and drug response profiling of high-grade serous ovarian cancer organoids

Project description:The broad research use of organoids from high-grade serous ovarian carcinoma (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23-38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.

2023-04-03 | GSE202263 | GEO

Ovarian Tumor Samples: mixed reference of 106 pooled ovarian samples vs. individual patient ovarian sample

Project description:The goal of the study was to identify molecular subgroups that might predict clinical outcomes in serous epithelial ovarian cancer (EOC) patients. A second objective was to identify potential therapeutic targets for serous EOC based on improved understanding of the molecular diversity of the disease. Ovarian tissues and matched peripheral blood samples were prospectively obtained from sequential patients undergoing planned gynecologic surgery at Cedars-Sinai Medical Center between 1989 and 2005. All patients underwent surgery and received adjuvant chemotherapy with a contemporaneous standard-of-care regimen. Ovarian tissue samples (n=172) were compared to a reference pool of 106 ovarian samples. Mixed reference includes normal, benign, borderline, and malignant samples.

2013-12-26 | E-GEOD-51088 | biostudies-arrayexpress

Homo sapiens

Project description:A rare case of phaeohyphomycosis caused by Corynespora cassiicola, a plant pathogen, and retrospective analysis of published reports

| PRJNA847991 | ENA

Project description:Discovery of novel associations between known and unknown pathogenic genetic mutations and rare diseases: A Collage of Case Reports

| PRJNA532328 | ENA

Transcription profiling of human late-stage, high-grade papillary serous ovarian adenocarcinomas

Project description:To demonstrate the use of a whole-genome oligonucleotide array to perform expression profiling on a series of microdissected late-stage, high-grade papillary serous ovarian adenocarcinomas to establish a prognostic gene signature correlating with survival and to identify novel survival factors in ovarian cancer. Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. We identify and validate a prognostic gene expression signature correlating with survival in a series of microdissected serous ovarian tumors. Experiment Overall Design: We identified 53 advanced stage, high-grade primary tumor specimens and 10 normal ovarian surface epithelium (OSE) brushings.

2009-10-23 | E-GEOD-18520 | biostudies-arrayexpress

Changes in the tumor microenvironment mark transition from serous borderline tumor to low grade serous carcinoma

Project description:Low grade serous ovarian cancer (LGSC) is a rare subtype of ovarian cancer, characterized by a slow growth rate, resistance to current treatment regimens, multiple recurrences and poor survival. LGSC arise from serous borderline tumor (SBT), however the mechanism of transformation is poorly understood. To better understand the biology of serous ovarian tumors, we performed whole proteome profiling of LGSC, SBT and the more common high grade serous (HGSC) ovarian tumors. Proteins associated with the tumor microenvironment were differentially expressed between LGSC and SBT or HGSC. In particular, fibroblast activation protein (FAP), a protein expressed in cancer associated fibroblasts, is abundantly expressed in LGSC. Furthermore, Tregs and M2 macrophages are more abundant in the stroma of LGSC compared to SBT. Together these data suggest that the tumor microenvironment provides a supportive environment for LGSC tumorigenesis and progression, and that targeting the tumor microenvironment of LGSC may be a viable therapeutic strategy.

2024-08-15 | PXD046360 | Pride

Mus musculus

Project description:Wild Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell survival

| PRJNA150207 | ENA